Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

TB

- PMLiVE

New virtual health and care report from WHO and Novartis calls for ‘critical action’

The report analysis shows how COVID-19 has changed virtual health and care policies in 23 countries

Roche Basel Switzerland

Roche collaborates with Global Fund to strengthen critical diagnostics infrastructure

The partnership is focused on helping patients with HIV and TB in low- and middle-income countries

- PMLiVE

WHO releases estimates of 14.9 million excess deaths during COVID-19 pandemic

The estimates show the full death toll caused directly or indirectly by the COVID-19 pandemic between 1 January 2020 and 31 December 2021

- PMLiVE

WHO issues prequalification for Roche’s Actemra/RoActemra for severe or critical COVID-19

The prequalification confirms the treatment meets WHO’s standards for quality, effectiveness and safety

- PMLiVE

Omicron prompts global action

A new variant of concern discovered in southern Africa is quickly spreading around the world, prompting government to take action

- PMLiVE

WHO recommends ‘life-saving’ IL-6 inhibitors for severe COVID-19

Roche's Actemra and Sanofi's Kevzara are included in WHO's updated patient care guidelines

- PMLiVE

Sinovac’s COVID-19 vaccine receives WHO emergency use listing

Vaccine found to be 51% effective in preventing symptomatic disease, meeting the WHO's recommendation of at least 50% efficacy

- PMLiVE

China’s Sinopharm given WHO emergency use listing for COVID-19 vaccine

WHO said decision gives the 'green light' for the vaccine to be rolled out globally

- PMLiVE

WHO to review Moderna’s COVID-19 vaccine for emergency use listing this week

WHO is also due to review vaccines from Sinopharm and Sinovac for possible EUAs

- PMLiVE

WHO director-general says pandemic can be brought under control within months

World has tools to curb pandemic if applied ‘consistently and equitably’

- PMLiVE

WHO backs emergency use of J&J’s one-dose COVID-19 vaccine

Vaccine is already approved for emergency use by the European Commission and the FDA

- PMLiVE

J&J submits one-dose COVID-19 vaccine to WHO for emergency use listing

In phase 3, J&J's vaccine was 66% effective overall at preventing moderate-to-severe COVID-19

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links